Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin + Taxane in Relapsed HER2+ Metastatic Breast Cancer
NCT01301729Phase 4Completed
- Sponsor
- Roche
- Start
- Mar 2011
- Primary completion
- Jul 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of trastuzumab in HER2-positive metastatic breast cancer, sponsored by Roche. Started Mar 2011; status: completed.
02
Drugs
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01301729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01301729.